• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Hematology

Latest News

Acute myeloid leukemia cells | Image credit: LASZLO - stock.adobe.com
Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

June 12th 2025

Revumenib shows promise for high-risk patients with acute myeloid leukemia (AML) with specific genetic mutations, demonstrating efficacy with no new safety signals.

The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological cancers. | Image credit: wladimir1804 - AdobeStock_408414612
FDA Approves Tablet Formulation of Zanubrutinib for All Indications

June 11th 2025

Mansi Shah, MD
Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

June 11th 2025

While improvements were seen in non-relapse mortality in CLL throughout the decade, the researchers observed no differences in overall survival or progression-free survival. | Image credit: LASZLO - stock.adobe.com
New Era of CLL Treatments Brings Changes to Use of HSCT

June 9th 2025

The investigators said real-world use of allo-SCT appeared to be receding as a preferred option after relapse, even before these new data. | Image credit: ibreakstock - stock.adobe.com
Auto-SCT Superior to Allo-SCT in Relapsed Myeloma After First-Line Auto-SCT

June 7th 2025

<1
...
2324252627
© 2025 MJH Life Sciences
AJMC®
All rights reserved.